Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
April 14, 2016

M&A this week: Advantis, Sequence Therapy, Madrigal Pharma, Synta Pharma

Advantis Corp., has acquired a 25% stake in US-based pain management and physical therapy company Sequence Therapy, LLC, which sees an exponential growth in revenue, from the current $0.5m a year, with the addition of the app-based revenue.

Advantis Corp., has acquired a 25% stake in US-based pain management and physical therapy company Sequence Therapy, LLC, which sees an exponential growth in revenue, from the current $0.5m a year, with the addition of the app-based revenue.

The acquisition will help Advantis to provide license-based digital application technology and achieve long-lasting results in the treatment of chronic pain.

Madrigal Pharmaceuticals, Inc. has announced a definitive agreement to merge with Synta Pharmaceuticals Corp.

The all-stock transaction will result in the merger of Madrigal with Synta’s wholly-owned subsidiary Saffron Merger Sub, Inc.

The merged entity will focus on developing small-molecule drugs to meet major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU